Aggressive silent corticotroph adenoma progressing to pituitary carcinoma. The role of temozolomide therapy

Hormones

Volumn 10, Issue 2, 2011, Pages 162-167

  Moshkin, Olga ^a,i   Syro, Luis V ^b   Scheithauer, Bernd W ^c   Ortiz, Leon D ^d   Fadul, Camilo E ^e   Uribe, Humberto ^f   Gonzalez, Ricardo ^g   Cusimano, Michael ^h   Horvath, Eva ⁱ   Rotondo, Fabio ⁱ   Kovacs, Kalman ⁱ  

^a Peterborough Regional Health Centre   (Canada)

^b HOSPITAL PABLO TOBÓN URIBE   (Colombia)

^c MAYO CLINIC   (United States)

^d Section of Neuro oncology   (Colombia)

^e DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^f Clinica SOMA   (Colombia)

^g Centro de Investigación Clínica Clinica Medellin Poblado   (Colombia)

^h Laboratory Medicine   (Canada)

ⁱ ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Carcinoma; MGMT; Pituitary adenoma; Temozolomide; Treatment

Indexed keywords

BEVACIZUMAB; CORTICOTROPIN; DNA TOPOISOMERASE (ATP HYDROLYSING); FOLLITROPIN; GROWTH HORMONE; HYDROCORTISONE; KI 67 ANTIGEN; LUTEINIZING HORMONE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROLACTIN; SOMATOMEDIN C; TEMOZOLOMIDE; THYROTROPIN; THYROXINE; VASCULOTROPIN;

ACTH SECRETING ADENOMA; ADULT; ARTICLE; BLINDNESS; BRAIN CANCER; CANCER RADIOTHERAPY; CASE REPORT; CELL PROLIFERATION; CONSTIPATION; CRANIAL NERVE PARALYSIS; DISEASE FREE SURVIVAL; FATIGUE; HUMAN; HYPOPITUITARISM; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROSURGERY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; SPINE METASTASIS; THROMBOCYTOPENIA; TRANSSPHENOIDAL SURGERY; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 79959271936     PISSN: 11093099     EISSN: None     Source Type: Journal    
DOI: 10.14310/horm.2002.1307     Document Type: Article

References (24)

1. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C, 1997 Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23: 35-61.
2. Yung WK, 2000 Temozolomide in malignant gliomas. Semin Oncol 27: 27-34.
3. Hegi ME, Diserens AC, Gorlia T, et al, 2005 Mgmt gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003.
4. Levin N, Lavon I, Zelikovitsh B, et al, 2006 Progressive low-grade oligodendrogliomas: Response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 106: 1759-1765.
5. Mohammed S, Kovacs K, Mason W, Smyth H, Cusimano MD, 2009 Use of temozolomide in aggressive pituitary tumors: Case report. Neurosurgery 64: E773-E774.
6. Hagen C, Schroeder HD, Hansen S, Hagen C, Andersen M, 2009 Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol 161: 631-637.
7. Matsuno A, 2009 Recent trends in the pathophysiology and treatment of pituitary adenomas. Brain Nerve 61: 957-962.
8. Kovacs K, Horvath E, Syro LV, et al, 2007 Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings. Hum Pathol 38: 185-189.
9. Agarwala SS, Kirkwood JM, 2000 Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 5: 144-151.
10. Kovacs K, Stefaneanu L, Horvath E, et al, 1991 Effect of dopamine agonist medication on prolactin producing pituitary adenomas. A morphological study including immunocytochemistry, electron microscopy and in situ hybridization. Virchows Arch A Pathol Anat Histopathol 418: 439-446.
11. Kaltsas GA, Mukherjee JJ, Plowman PN, Monson JP, Grossman AB, Besser GM, 1998 The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. J Clin Endocrinol Metab 83: 4233-4238.
12. Lamers LM, Stupp R, van den Bent MJ, et al, 2008 Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: A report from the eortc 26981/22981 nci-c ce3 intergroup study. Cancer 112: 1337-1344.
13. Quirt I, Verma S, Petrella T, Bak K, Charette M, 2007 Temozolomide for the treatment of metastatic melanoma: A systematic review. Oncologist 12: 1114-1123.
14. Ekeblad S, Sundin A, Janson ET, et al, 2007 Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 13: 2986-2991.
15. Kovacs K, Scheithauer BW, Lombardero M, et al, 2008 Mgmt immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol 115: 261-262.
16. Neff LM, Weil M, Cole A, et al, 2007 Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary 10: 81-86.
17. Fadul CE, Kominsky AL, Kingman LS, et al, 2004 Pituitary carcinomas respond to temozolomide. Neuro-Onc 6: 374.
18. Lim S, Shahinian H, Maya MM, Yong W, Heaney AP, 2006 Temozolomide: A novel treatment for pituitary carcinoma. Lancet Oncol 7: 518-520
19. Fadul CE, Kominsky AL, Meyer LP, et al, 2006 Longterm response of pituitary carcinoma to temozolomide. Report of two cases. J Neurosurg 105: 621-626.
20. Maruya S, Shirasaki T, Nagaki T, et al, 2009 Differential expression of topoisomerase II alpha protein in salivary gland carcinomas: Histogenetic and prognostic implications. BMC Cancer 9: 72.
21. Nakopoulou L, Zervas A, Lazaris AC, et al, 2001 Predictive value of topoisomerase II alpha immunostaining in urothelial bladder carcinoma. J Clin Pathol 54: 309-313.
22. Lee A, LiVolsi VA, Baloch ZW, 2000 Expression of DNA topoisomerase II alpha in thyroid neoplasia. Mod Pathol 13: 396-400.
23. Widhalm G, Wolfsberger S, Preusser M, et al, 2009 O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: Are progressive tumors potential candidates for temozolomide treatment? Cancer 115: 1070-1080.
24. Karavitaki N, Ansorge O, Wass JA, 2007 Silent corticotroph adenomas. Arq Bras Endocrinol Metabol 51: 1314-1318.